Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04815967CT.gov Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity | — | Terminated | — | — | — |
NCT02052024CT.gov Myobloc Atrophy Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Botulinum B Toxin (this asset) | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | Approved | BB · 65 |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Tirofiban | Weifang Medical University | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Botulinum B Toxin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Brain Injury | — | P4 | B · 61 |
| Neoplasm | — | P4 | B · 61 |
| Cerebral Palsy | — | P2/3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Botulinum B Toxin in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/botulinum-b-toxin-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →